Development of a Method for Converting a TAK1 Type I Inhibitor into a Type II or c-Helix-Out Inhibitor by Structure-Based Drug Design (SBDD)
Muraoka, T., Ide, M., Irie, M., Morikami, K., Miura, T., Nishihara, M., Kashiwagi, H.(2016) Chem Pharm Bull (Tokyo) 64: 1622-1629
- PubMed: 27803473 
- DOI: 10.1248/cpb.c16-00606
- Primary Citation of Related Structures:  
5GJD, 5GJG, 5GJF - PubMed Abstract: 
We have developed a method for converting a transforming growth factor-β-activated kinase 1 (TAK1) type I inhibitor into a type II or c-helix-out inhibitor by structure-based drug design (SBDD) to achieve an effective strategy for developing these different types of kinase inhibitor in parallel ...